http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 23 Feb 2026 16:37:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Lantern+Pharma+Inc.++++++++++++++++++++Filed+by%3A+Bios+Equity+Partners%2C+LP/26044072.html si-local-file:///var/storage/secattach/20260223/26044072.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Lantern+Pharma+Inc.++++++++++++++++++++Filed+by%3A+Bios+Equity+Partners%2C+LP/26044072.html Mon, 23 Feb 2026 16:37:00 -0500 LTRN O.47731837 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Lantern+Pharma+Inc.++++++++++++++++++++Filed+by%3A+Bios+Equity+Partners%2C+LP/26044072.html si-local-file:///var/storage/secattach/20260223/26044072.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Lantern+Pharma+Inc.++++++++++++++++++++Filed+by%3A+Bios+Equity+Partners%2C+LP/26044072.html Mon, 23 Feb 2026 16:37:00 -0500 LTRN O.47731837 http://www.streetinsider.com/Press+Releases/Lantern+Pharma+to+Present+at+the+7th+Glioblastoma+Drug+Development+Summit+in+Boston+on+February+17-19%2C+2026/25972131.html <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence to accelerate oncology drug discovery and development, today announced that CEO and President Panna Sharma will present at the 7th Glioblastoma Drug Development Summit, February 17–19, 2026, in Boston, MA. </p><p> More information about the summit is available at: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fglioblastoma-drugdevelopment.com%2F&amp;esheet=54421462&amp;newsitemid=20260210506555&amp;lan=en-US&amp;anchor=https%3A%2F%2Fglioblastoma-drugdevelopment.com&amp;index=1&amp;md5=e1babd0c6c5cdb783c5b96c2b972eeea" shape="rect">https://glioblastoma-drugdevelopment.com</a>. </p><p> Lantern’s proprietary AI and machine learning platform, RADR®, powered the development of LP-184 / STAR-001, a novel brain-penetrant therapeutic candidate. This work has driven the creation of Lantern’s wholly owned subsidiary, Starlight Therapeutics, which is advancing clinical development for multiple CNS cancers, http://www.streetinsider.com/Press+Releases/Lantern+Pharma+to+Present+at+the+7th+Glioblastoma+Drug+Development+Summit+in+Boston+on+February+17-19%2C+2026/25972131.html Tue, 10 Feb 2026 08:45:00 -0500 LTRN O.47731837 http://www.streetinsider.com/Press+Releases/Lantern+Pharma+to+Present+at+the+7th+Glioblastoma+Drug+Development+Summit+in+Boston+on+February+17-19%2C+2026/25972131.html <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence to accelerate oncology drug discovery and development, today announced that CEO and President Panna Sharma will present at the 7th Glioblastoma Drug Development Summit, February 17–19, 2026, in Boston, MA. </p><p> More information about the summit is available at: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fglioblastoma-drugdevelopment.com%2F&amp;esheet=54421462&amp;newsitemid=20260210506555&amp;lan=en-US&amp;anchor=https%3A%2F%2Fglioblastoma-drugdevelopment.com&amp;index=1&amp;md5=e1babd0c6c5cdb783c5b96c2b972eeea" shape="rect">https://glioblastoma-drugdevelopment.com</a>. </p><p> Lantern’s proprietary AI and machine learning platform, RADR®, powered the development of LP-184 / STAR-001, a novel brain-penetrant therapeutic candidate. This work has driven the creation of Lantern’s wholly owned subsidiary, Starlight Therapeutics, which is advancing clinical development for multiple CNS cancers, http://www.streetinsider.com/Press+Releases/Lantern+Pharma+to+Present+at+the+7th+Glioblastoma+Drug+Development+Summit+in+Boston+on+February+17-19%2C+2026/25972131.html Tue, 10 Feb 2026 08:45:00 -0500 LTRN O.47731837 http://www.streetinsider.com/Business+Wire/Lantern+Pharma+to+Present+at+the+7th+Glioblastoma+Drug+Development+Summit+in+Boston+on+February+17-19%2C+2026/25972131.html <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence to accelerate oncology drug discovery and development, today announced that CEO and President Panna Sharma will present at the 7th Glioblastoma Drug Development Summit, February 17–19, 2026, in Boston, MA. </p><p> More information about the summit is available at: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fglioblastoma-drugdevelopment.com%2F&amp;esheet=54421462&amp;newsitemid=20260210506555&amp;lan=en-US&amp;anchor=https%3A%2F%2Fglioblastoma-drugdevelopment.com&amp;index=1&amp;md5=e1babd0c6c5cdb783c5b96c2b972eeea" shape="rect">https://glioblastoma-drugdevelopment.com</a>. </p><p> Lantern’s proprietary AI and machine learning platform, RADR®, powered the development of LP-184 / STAR-001, a novel brain-penetrant therapeutic candidate. This work has driven the creation of Lantern’s wholly owned subsidiary, Starlight Therapeutics, which is advancing clinical development for multiple CNS cancers, http://www.streetinsider.com/Business+Wire/Lantern+Pharma+to+Present+at+the+7th+Glioblastoma+Drug+Development+Summit+in+Boston+on+February+17-19%2C+2026/25972131.html Tue, 10 Feb 2026 08:45:00 -0500 LTRN O.47731837 http://www.streetinsider.com/Business+Wire/Lantern+Pharma+to+Present+at+the+7th+Glioblastoma+Drug+Development+Summit+in+Boston+on+February+17-19%2C+2026/25972131.html <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence to accelerate oncology drug discovery and development, today announced that CEO and President Panna Sharma will present at the 7th Glioblastoma Drug Development Summit, February 17–19, 2026, in Boston, MA. </p><p> More information about the summit is available at: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fglioblastoma-drugdevelopment.com%2F&amp;esheet=54421462&amp;newsitemid=20260210506555&amp;lan=en-US&amp;anchor=https%3A%2F%2Fglioblastoma-drugdevelopment.com&amp;index=1&amp;md5=e1babd0c6c5cdb783c5b96c2b972eeea" shape="rect">https://glioblastoma-drugdevelopment.com</a>. </p><p> Lantern’s proprietary AI and machine learning platform, RADR®, powered the development of LP-184 / STAR-001, a novel brain-penetrant therapeutic candidate. This work has driven the creation of Lantern’s wholly owned subsidiary, Starlight Therapeutics, which is advancing clinical development for multiple CNS cancers, http://www.streetinsider.com/Business+Wire/Lantern+Pharma+to+Present+at+the+7th+Glioblastoma+Drug+Development+Summit+in+Boston+on+February+17-19%2C+2026/25972131.html Tue, 10 Feb 2026 08:45:00 -0500 LTRN O.47731837 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Lantern+Pharma+Inc.+++++++For%3A+Jan+22/25884163.html si-local-file:///var/storage/secattach/20260123/25884163.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Lantern+Pharma+Inc.+++++++For%3A+Jan+22/25884163.html Fri, 23 Jan 2026 07:31:00 -0500 LTRN O.47731837 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Lantern+Pharma+Inc.+++++++For%3A+Jan+22/25884163.html si-local-file:///var/storage/secattach/20260123/25884163.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Lantern+Pharma+Inc.+++++++For%3A+Jan+22/25884163.html Fri, 23 Jan 2026 07:31:00 -0500 LTRN O.47731837 http://www.streetinsider.com/Corporate+News/Lantern+Pharma%27s+LP-284+gets+FDA+orphan+drug+status+for+soft+tissue+sarcoma/25864983.html <p>Lantern Pharma Inc. (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to LP-284 for treating soft tissue sarcomas.</p><p>This marks the third orphan designation for LP-284, following previous designations for Mantle Cell Lymphoma in January 2023 and High-Grade B-Cell Lymphoma with MYC and BCL2 rearrangements in November 2023. The company now has six total orphan designations across its clinical programs.</p><p>Soft tissue sarcomas are rare cancers developing in tissues that connect, support and surround body structures. The National Cancer Institute's SEER Program estimates approximately 13,520 new cases will be diagnosed in the United States in http://www.streetinsider.com/Corporate+News/Lantern+Pharma%27s+LP-284+gets+FDA+orphan+drug+status+for+soft+tissue+sarcoma/25864983.html Tue, 20 Jan 2026 08:04:34 -0500 LTRN http://www.streetinsider.com/FDA/Lantern+Pharma%27s+LP-284+gets+FDA+orphan+drug+status+for+soft+tissue+sarcoma/25864983.html <p>Lantern Pharma Inc. (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to LP-284 for treating soft tissue sarcomas.</p><p>This marks the third orphan designation for LP-284, following previous designations for Mantle Cell Lymphoma in January 2023 and High-Grade B-Cell Lymphoma with MYC and BCL2 rearrangements in November 2023. The company now has six total orphan designations across its clinical programs.</p><p>Soft tissue sarcomas are rare cancers developing in tissues that connect, support and surround body structures. The National Cancer Institute's SEER Program estimates approximately 13,520 new cases will be diagnosed in the United States in http://www.streetinsider.com/FDA/Lantern+Pharma%27s+LP-284+gets+FDA+orphan+drug+status+for+soft+tissue+sarcoma/25864983.html Tue, 20 Jan 2026 08:04:34 -0500 LTRN http://www.streetinsider.com/Press+Releases/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html <ul class="bwlistdisc"> <li> Third FDA orphan designation for LP-284; Sixth overall for Lantern’s A.I.-driven precision oncology pipeline </li> <li> Orphan designation expands LP-284's potential for an estimated ~96,000 global annual soft tissue sarcoma cases; annual market valued at $2.4 billion in 2025 and projected to reach $4.7 billion by 2035 </li> </ul> <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LP-284 for the treatment of soft tissue sarcomas. </p><p> This marks http://www.streetinsider.com/Press+Releases/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html Tue, 20 Jan 2026 08:00:00 -0500 A.06822034 A.19655944 A.60001765 LTRN O.03307993 O.20026344 O.20738543 O.47731837 http://www.streetinsider.com/Press+Releases/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html <ul class="bwlistdisc"> <li> Third FDA orphan designation for LP-284; Sixth overall for Lantern’s A.I.-driven precision oncology pipeline </li> <li> Orphan designation expands LP-284's potential for an estimated ~96,000 global annual soft tissue sarcoma cases; annual market valued at $2.4 billion in 2025 and projected to reach $4.7 billion by 2035 </li> </ul> <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LP-284 for the treatment of soft tissue sarcomas. </p><p> This marks http://www.streetinsider.com/Press+Releases/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html Tue, 20 Jan 2026 08:00:00 -0500 A.06822034 A.19655944 A.60001765 LTRN O.03307993 O.20026344 O.20738543 O.47731837 http://www.streetinsider.com/Press+Releases/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html <ul class="bwlistdisc"> <li> Third FDA orphan designation for LP-284; Sixth overall for Lantern’s A.I.-driven precision oncology pipeline </li> <li> Orphan designation expands LP-284's potential for an estimated ~96,000 global annual soft tissue sarcoma cases; annual market valued at $2.4 billion in 2025 and projected to reach $4.7 billion by 2035 </li> </ul> <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LP-284 for the treatment of soft tissue sarcomas. </p><p> This marks http://www.streetinsider.com/Press+Releases/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html Tue, 20 Jan 2026 08:00:00 -0500 A.06822034 A.19655944 A.60001765 LTRN O.03307993 O.20026344 O.20738543 O.47731837 http://www.streetinsider.com/Press+Releases/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html <ul class="bwlistdisc"> <li> Third FDA orphan designation for LP-284; Sixth overall for Lantern’s A.I.-driven precision oncology pipeline </li> <li> Orphan designation expands LP-284's potential for an estimated ~96,000 global annual soft tissue sarcoma cases; annual market valued at $2.4 billion in 2025 and projected to reach $4.7 billion by 2035 </li> </ul> <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LP-284 for the treatment of soft tissue sarcomas. </p><p> This marks http://www.streetinsider.com/Press+Releases/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html Tue, 20 Jan 2026 08:00:00 -0500 A.06822034 A.19655944 A.60001765 LTRN O.03307993 O.20026344 O.20738543 O.47731837 http://www.streetinsider.com/Press+Releases/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html <ul class="bwlistdisc"> <li> Third FDA orphan designation for LP-284; Sixth overall for Lantern’s A.I.-driven precision oncology pipeline </li> <li> Orphan designation expands LP-284's potential for an estimated ~96,000 global annual soft tissue sarcoma cases; annual market valued at $2.4 billion in 2025 and projected to reach $4.7 billion by 2035 </li> </ul> <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LP-284 for the treatment of soft tissue sarcomas. </p><p> This marks http://www.streetinsider.com/Press+Releases/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html Tue, 20 Jan 2026 08:00:00 -0500 A.06822034 A.19655944 A.60001765 LTRN O.03307993 O.20026344 O.20738543 O.47731837 http://www.streetinsider.com/Press+Releases/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html <ul class="bwlistdisc"> <li> Third FDA orphan designation for LP-284; Sixth overall for Lantern’s A.I.-driven precision oncology pipeline </li> <li> Orphan designation expands LP-284's potential for an estimated ~96,000 global annual soft tissue sarcoma cases; annual market valued at $2.4 billion in 2025 and projected to reach $4.7 billion by 2035 </li> </ul> <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LP-284 for the treatment of soft tissue sarcomas. </p><p> This marks http://www.streetinsider.com/Press+Releases/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html Tue, 20 Jan 2026 08:00:00 -0500 A.06822034 A.19655944 A.60001765 LTRN O.03307993 O.20026344 O.20738543 O.47731837 http://www.streetinsider.com/Press+Releases/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html <ul class="bwlistdisc"> <li> Third FDA orphan designation for LP-284; Sixth overall for Lantern’s A.I.-driven precision oncology pipeline </li> <li> Orphan designation expands LP-284's potential for an estimated ~96,000 global annual soft tissue sarcoma cases; annual market valued at $2.4 billion in 2025 and projected to reach $4.7 billion by 2035 </li> </ul> <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LP-284 for the treatment of soft tissue sarcomas. </p><p> This marks http://www.streetinsider.com/Press+Releases/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html Tue, 20 Jan 2026 08:00:00 -0500 A.06822034 A.19655944 A.60001765 LTRN O.03307993 O.20026344 O.20738543 O.47731837 http://www.streetinsider.com/Press+Releases/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html <ul class="bwlistdisc"> <li> Third FDA orphan designation for LP-284; Sixth overall for Lantern’s A.I.-driven precision oncology pipeline </li> <li> Orphan designation expands LP-284's potential for an estimated ~96,000 global annual soft tissue sarcoma cases; annual market valued at $2.4 billion in 2025 and projected to reach $4.7 billion by 2035 </li> </ul> <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LP-284 for the treatment of soft tissue sarcomas. </p><p> This marks http://www.streetinsider.com/Press+Releases/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html Tue, 20 Jan 2026 08:00:00 -0500 A.06822034 A.19655944 A.60001765 LTRN O.03307993 O.20026344 O.20738543 O.47731837 http://www.streetinsider.com/Business+Wire/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html <ul class="bwlistdisc"> <li> Third FDA orphan designation for LP-284; Sixth overall for Lantern’s A.I.-driven precision oncology pipeline </li> <li> Orphan designation expands LP-284's potential for an estimated ~96,000 global annual soft tissue sarcoma cases; annual market valued at $2.4 billion in 2025 and projected to reach $4.7 billion by 2035 </li> </ul> <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LP-284 for the treatment of soft tissue sarcomas. </p><p> This marks http://www.streetinsider.com/Business+Wire/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html Tue, 20 Jan 2026 08:00:00 -0500 A.06822034 A.19655944 A.60001765 LTRN O.03307993 O.20026344 O.20738543 O.47731837 http://www.streetinsider.com/Business+Wire/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html <ul class="bwlistdisc"> <li> Third FDA orphan designation for LP-284; Sixth overall for Lantern’s A.I.-driven precision oncology pipeline </li> <li> Orphan designation expands LP-284's potential for an estimated ~96,000 global annual soft tissue sarcoma cases; annual market valued at $2.4 billion in 2025 and projected to reach $4.7 billion by 2035 </li> </ul> <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LP-284 for the treatment of soft tissue sarcomas. </p><p> This marks http://www.streetinsider.com/Business+Wire/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html Tue, 20 Jan 2026 08:00:00 -0500 A.06822034 A.19655944 A.60001765 LTRN O.03307993 O.20026344 O.20738543 O.47731837 http://www.streetinsider.com/Business+Wire/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html <ul class="bwlistdisc"> <li> Third FDA orphan designation for LP-284; Sixth overall for Lantern’s A.I.-driven precision oncology pipeline </li> <li> Orphan designation expands LP-284's potential for an estimated ~96,000 global annual soft tissue sarcoma cases; annual market valued at $2.4 billion in 2025 and projected to reach $4.7 billion by 2035 </li> </ul> <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LP-284 for the treatment of soft tissue sarcomas. </p><p> This marks http://www.streetinsider.com/Business+Wire/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html Tue, 20 Jan 2026 08:00:00 -0500 A.06822034 A.19655944 A.60001765 LTRN O.03307993 O.20026344 O.20738543 O.47731837 http://www.streetinsider.com/Business+Wire/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html <ul class="bwlistdisc"> <li> Third FDA orphan designation for LP-284; Sixth overall for Lantern’s A.I.-driven precision oncology pipeline </li> <li> Orphan designation expands LP-284's potential for an estimated ~96,000 global annual soft tissue sarcoma cases; annual market valued at $2.4 billion in 2025 and projected to reach $4.7 billion by 2035 </li> </ul> <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LP-284 for the treatment of soft tissue sarcomas. </p><p> This marks http://www.streetinsider.com/Business+Wire/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html Tue, 20 Jan 2026 08:00:00 -0500 A.06822034 A.19655944 A.60001765 LTRN O.03307993 O.20026344 O.20738543 O.47731837 http://www.streetinsider.com/Business+Wire/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html <ul class="bwlistdisc"> <li> Third FDA orphan designation for LP-284; Sixth overall for Lantern’s A.I.-driven precision oncology pipeline </li> <li> Orphan designation expands LP-284's potential for an estimated ~96,000 global annual soft tissue sarcoma cases; annual market valued at $2.4 billion in 2025 and projected to reach $4.7 billion by 2035 </li> </ul> <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LP-284 for the treatment of soft tissue sarcomas. </p><p> This marks http://www.streetinsider.com/Business+Wire/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html Tue, 20 Jan 2026 08:00:00 -0500 A.06822034 A.19655944 A.60001765 LTRN O.03307993 O.20026344 O.20738543 O.47731837 http://www.streetinsider.com/Business+Wire/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html <ul class="bwlistdisc"> <li> Third FDA orphan designation for LP-284; Sixth overall for Lantern’s A.I.-driven precision oncology pipeline </li> <li> Orphan designation expands LP-284's potential for an estimated ~96,000 global annual soft tissue sarcoma cases; annual market valued at $2.4 billion in 2025 and projected to reach $4.7 billion by 2035 </li> </ul> <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LP-284 for the treatment of soft tissue sarcomas. </p><p> This marks http://www.streetinsider.com/Business+Wire/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html Tue, 20 Jan 2026 08:00:00 -0500 A.06822034 A.19655944 A.60001765 LTRN O.03307993 O.20026344 O.20738543 O.47731837 http://www.streetinsider.com/Business+Wire/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html <ul class="bwlistdisc"> <li> Third FDA orphan designation for LP-284; Sixth overall for Lantern’s A.I.-driven precision oncology pipeline </li> <li> Orphan designation expands LP-284's potential for an estimated ~96,000 global annual soft tissue sarcoma cases; annual market valued at $2.4 billion in 2025 and projected to reach $4.7 billion by 2035 </li> </ul> <p> DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LP-284 for the treatment of soft tissue sarcomas. </p><p> This marks http://www.streetinsider.com/Business+Wire/Lantern+Pharma%27s+LP-284+Receives+FDA+Orphan+Drug+Designation+for+Soft+Tissue+Sarcomas/25864807.html Tue, 20 Jan 2026 08:00:00 -0500 A.06822034 A.19655944 A.60001765 LTRN O.03307993 O.20026344 O.20738543 O.47731837